keyword
MENU ▼
Read by QxMD icon Read
search

Goserelin

keyword
https://www.readbyqxmd.com/read/27900064/enzalutamide-induced-acute-generalized-exanthematous-pustulosis
#1
Chloé Alberto, Maria Polina Konstantinou, Catherine Martinage, Eline Casassa, Emilie Tournier, Haleh Bagheri, Vincent Sibaud, Loïc Mourey, Juliette Mazereeuw-Hautier, Nicolas Meyer, Carle Paul, Cristina Bulai Livideanu
INTRODUCTION: Enzalutamide (Xtandi®) is a new potent inhibitor of the signaling pathway for the androgen receptor with a half-life of 5.8 days. It has been on the market for the treatment of metastatic castration-resistant prostate cancer since November 2013. OBJECTIVE: We report the first case of acute generalized exanthematous pustulosis (AGEP) induced by enzalutamide. OBSERVATION: A 62-year-old male patient with no significant medical history, was diagnosed in April 2014 with metastatic prostatic adenocarcinoma...
November 13, 2016: Journal of Dermatological Case Reports
https://www.readbyqxmd.com/read/27847099/efficacy-of-switching-therapy-of-luteinizing-hormone-releasing-hormone-analogue-for-advanced-prostate-cancer
#2
Yuan-Chi Shen, Chih-Hsiung Kang, Po-Hui Chiang
This study was conducted to determine the efficacy of switching therapy with a second-line luteinizing hormone-releasing hormone (LHRH) analogue after prostate-specific antigen (PSA) progression for advanced prostate cancer. We enrolled 200 patients, from December 2005 to September 2013, with nodal positive, metastatic prostate cancer or disease progression after definite treatment receiving continuous LHRH analogue therapy with monthly depot leuprorelin(sc) acetate 3.75 mg/vial (LA) or goserelin acetate(sc) 3...
November 2016: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/27798900/what-characterizes-long-term-survivors-of-recurrent-ovarian-cancer-case-report-and-review-of-the-literature
#3
Ziad Hilal, Beate Schultheis, Franziska Hartmann, Askin Dogan, Cem Cetin, Harald Krentel, Sven Schiermeier, Clemens B Tempfer
BACKGROUND: Women with recurrent ovarian cancer have a poor prognosis and short survival. However, some women are long-term survivors and it is unclear whether they share specific common characteristics. CASE REPORT: We present the case of a 63-year-old woman with histologically-proven recurrent ovarian cancer and a survival time of 16 years after the diagnosis of recurrence. She underwent initial debulking surgery in 1994, followed by 6 cycles of adjuvant chemotherapy with cisplatin and paclitaxel...
October 2016: Anticancer Research
https://www.readbyqxmd.com/read/27697675/goserelin-plus-tamoxifen-compared-to-chemotherapy-followed-by-tamoxifen-in-premenopausal-patients-with-early-stage-lymph-node-negative-breast-cancer-of-luminal-a-subtype
#4
Mansoor Alramadhan, Jai Min Ryu, Musaed Rayzah, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Soo Youn Bae, Sungmin Park, Hyun-June Paik, Jeong Eon Lee
OBJECTIVES: To study the outcomes of adjuvant goserelin combined with tamoxifen (GosTam) compared to chemotherapy followed by tamoxifen (ChemTam) in premenopausal patients with early stage, luminal A breast cancer. METHODS: From 2008 until 2013, data were retrospectively collected for premenopausal patients who underwent surgery for invasive tumors that were ≤2.0 cm, node-negative, strongly positive for estrogen and progesterone receptors, HER-2-negative, and Ki-67 < 25%...
December 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27679555/elevated-levels-of-autophagy-related-marker-ulk1-and-mitochondrion-associated-autophagy-inhibitor-lrpprc-are-associated-with-biochemical-progression-and-overall-survival-after-androgen-deprivation-therapy-in-patients-with-metastatic-prostate-cancer
#5
Hong-Yi Zhang, Ya-Dong Ma, Ye Zhang, Jie Cui, Zi-Ming Wang
AIM: To evaluate the expression levels and prognostic significance of autophagy-related markers, UNC-51-like kinase1 (ULK1), Beclin1, microtubule-associated protein light chain 3 (LC3), autophagy-related gene 5 (ATG5) and mitochondrion-associated autophagy inhibitor, LRPPRC, in patients with metastatic prostate cancer (PCa) after androgen deprivation therapy (ADT). METHODS: Expressions of ULK1, Beclin1, LC3, ATG5 and LRPPRC were assessed by immunohistochemical examination in 198 patients with metastatic PCa who were receiving ADT (goserelin and bicalutamide)...
September 27, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27649641/pharmacologically-induced-sex-hormone-fluctuation-effects-on-resting-state-functional-connectivity-in-a-risk-model-for-depression-a-randomized-trial
#6
Patrick MacDonald Fisher, Camilla Borgsted Larsen, Vincent Beliveau, Susanne Henningsson, Anja Pinborg, Klaus Kähler Holst, Peter Steen Jensen, Claus Svarer, Hartwig Roman Siebner, Gitte Moos Knudsen, Vibe Gedsoe Frokjaer
Women are at relatively greater lifetime risk for depression than men. This elevated risk in women is partly due to heightened risk during time periods characterized by marked fluctuations in sex hormones, including postpartum and perimenopausal periods. How sex hormone fluctuations contribute to heightened risk is not fully understood but may involve intrinsic functional connectivity. We induced a biphasic ovarian sex hormone fluctuation using the gonadotropin-releasing hormone agonist (GnRHa) goserelin to determine, with a randomized placebo-controlled design, intervention effects on or GnRHa-provoked depressive symptoms associations with change in resting-state functional connectivity (rs-FC) in 58 healthy women for six seeds (amygdala, hippocampus, anterior cingulate cortex, dorsal raphe, median raphe, and posterior cingulate cortex)...
October 19, 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27633684/peptide-therapeutics-and-the-pharmaceutical-industry-barriers-encountered-translating-from-the-laboratory-to-patients
#7
John Rafferty, Hema Nagaraj, Alice P McCloskey, Rawan Huwaitat, Simon Porter, Alyaa Albadr, Garry Laverty
Peptides are receiving increasing interest as clinical therapeutics. These highly tunable molecules can be tailored to achieve desirable biocompatibility and biodegradability with simultaneously selective and potent therapeutic effects. Despite challenges regarding up-scaling and licensing of peptide products, their vast clinical potential is reflected in the 60 plus peptide-based therapeutics already on the market, and the further 500 derivatives currently in developmental stages. Peptides are proving effective for a multitude of disease states including: type 2 diabetes (controlled using the licensed glucagon-like peptide-1 receptor liraglutide); irritable bowel syndrome managed with linaclotide (currently at approval stages); acromegaly (treated with octapeptide somostatin analogues lanreotide and octreotide); selective or broad spectrum microbicidal agents such as the Gram-positive selective PTP-7 and antifungal heliomicin; anticancer agents including goserelin used as either adjuvant or monotherapy for prostate and breast cancer, and the first marketed peptide derived vaccine against prostate cancer, sipuleucel-T...
September 9, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27586506/a-comparative-study-on-the-efficacies-of-gonadotropin-releasing-hormone-gnrh-agonist-and-gnrh-antagonist-in-neoadjuvant-androgen-deprivation-therapy-combined-with-transperineal-prostate-brachytherapy-for-localized-prostate-cancer
#8
Kenta Miki, Hiroshi Sasaki, Masahito Kido, Hiroyuki Takahashi, Manabu Aoki, Shin Egawa
BACKGROUND: Neoadjuvant androgen deprivation therapy (ADT) has been suggested to confer several clinical benefits in patients with prostate cancer (PCa) undergoing transperineal prostate brachytherapy (TPPB). Unlike gonadotropin-releasing hormone (GnRH) receptor agonists, a GnRH antagonist such as degarelix can achieve castrate levels of testosterone without testosterone flare. However, normalization of serum testosterone levels following completion of neoadjuvant ADT in either form of treatment has never been compared in clinical trials...
September 1, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27542707/recurrent-massive-ascites-due-to-mossy-endometriosis
#9
Erica C Dun, Serena Wong, Nisha A Lakhi, Ceana H Nehzat
OBJECTIVE: To report the medical and surgical management of a rare case of recurrent moss-like endometriosis and associated hemorrhagic ascites. DESIGN: Video description of the case, demonstration of the surgical technique, discussion of the histology, and review of endometriosis-associated ascites. SETTING: Tertiary referral center. PATIENT(S): A 26-year-old nulliparous woman of Nigerian heritage with recurrent hemorrhagic ascites due to endometriosis...
August 16, 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27390687/degarelix-for-the-treatment-of-advanced-prostate-cancer-compared-with-gnrh-agonists-a-systematic-review-and-meta-analysis
#10
Seyed Alireza Hosseini, Fatemeh Rajabi, Ali Akbari Sari, Mohsen Ayati, Saeed Heidari, Fawzieh Ghamary
BACKGROUND: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. METHODS: MEDLINE, Web of Science and the Cochrane library were searched to identify all of the published Randomized Controlled Trials (RCTs) that used degarelix versus gonadotropin-releasing hormone agonists with or without anti-androgen therapy for the treatment of prostate cancer...
2016: Medical Journal of the Islamic Republic of Iran
https://www.readbyqxmd.com/read/27389059/goserelin-toxicities-and-preferences-for-ovarian-suppression-method-in-pre-menopausal-women-with-breast-cancer
#11
Amy Hsin-Chieh Hsieh, Ganessan Kichenadasse, Sina Vatandoust, Amitesh Roy, Shawgi Sukumaran, Christos S Karapetis, Helen Martin, Li Chia Chong, Bogda Koczwara
BACKGROUND: Goserelin, a form of medical ovarian suppression (MOS), is an effective treatment for premenopausal women with breast cancer (PMBC). Meta-analysis data showed that similar efficacy is achieved with MOS and non-pharmacological ovarian suppression (NPOS) - oophorectomy or ovarian irradiation. Acceptance rate of NPOS remains low. AIMS: This study explored the reported toxicities of PMBC women and their preferred ovarian suppression method whilst on goserelin...
July 8, 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27368881/palbociclib-in-combination-with-fulvestrant-in-women-with-hormone-receptor-positive-her2-negative-advanced-metastatic-breast-cancer-detailed-safety-analysis-from-a-multicenter-randomized-placebo-controlled-phase-iii-study-paloma-3
#12
Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, Angela M DeMichele, Sherene Loi, Jungsil Ro, Marco Colleoni, Hiroji Iwata, Nadia Harbeck, Massimo Cristofanilli, Ke Zhang, Alexandra Thiele, Nicholas C Turner, Hope S Rugo
BACKGROUND: Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it is clinically important to understand palbociclib's safety profile to effectively manage toxicity and optimize clinical benefit. MATERIALS AND METHODS: Patients with endocrine-resistant, HR-positive/HER2-negative MBC (n = 521) were randomly assigned 2:1 to receive fulvestrant (500 mg intramuscular injection) with or without goserelin with oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo...
October 2016: Oncologist
https://www.readbyqxmd.com/read/27300575/effects-of-testosterone-and-estradiol-deficiency-on-vasomotor-symptoms-in-hypogonadal-men
#13
Alexander P Taylor, Hang Lee, Matthew L Webb, Hadine Joffe, Joel S Finkelstein
CONTEXT: The hormonal basis of vasomotor symptoms (VMS) in hypogonadal men is incompletely understood. OBJECTIVE: To determine the contributions of testosterone and estradiol deficiency to VMS in hypogonadal men. DESIGN: Two randomized trials were conducted sequentially between September 2004 and April 2011. Controls were recruited separately. SETTING: A single-site academic medical center. PARTICIPANTS: Healthy men ages 20-50, with normal serum testosterone levels...
September 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27234217/slco1b1-5-polymorphism-rs4149056-is-associated-with-chemotherapy-induced-amenorrhea-in-premenopausal-women-with-breast-cancer-a-prospective-cohort-study
#14
Toralf Reimer, Sarah Kempert, Bernd Gerber, Hans-Jürgen Thiesen, Steffi Hartmann, Dirk Koczan
BACKGROUND: Because inheritance is recognized as playing a role in age at menarche and natural menopause, the development of chemotherapy-induced amenorrhea (CIA) might depend on inherited genetic factors; however, studies that explore such a correlation are few and have received scant attention. Given the importance of this topic we conducted a comprehensive genotype study in young women (≤45 years) with early-stage breast cancer. METHODS: Our approach tested the effect of variant polymorphisms in drug metabolism enzymes (DMEs) using a predesigned pharmacogenomics panel (TaqMan® OpenArray®, Life Technologies GmbH, Darmstadt, Germany) in premenopausal women (n = 50)...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27225336/dienogest-compared-with-gonadotropin-releasing-hormone-agonist-after-conservative-surgery-for-endometriosis
#15
Yotaro Takaesu, Hirotaka Nishi, Junya Kojima, Toru Sasaki, Yuzo Nagamitsu, Rina Kato, Keiichi Isaka
AIM: Although there are various hormone therapies, including gonadotropin-releasing hormone agonist, danazol, levonorgestrel-releasing intrauterine system, dienogest, and low-dose estrogen progestin, no consensus opinion has been reached in terms of which medication should be used and for how long it should be administered. We aimed to determine whether dienogest or goserelin is the better postoperative therapy to prevent recurrence of endometriosis. METHODS: A prospective cohort randomized study were conducted, including 198 patients diagnosed as having endometriosis...
September 2016: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/27197523/the-role-of-the-addition-of-ovarian-suppression-to-tamoxifen-in-young-women-with-hormone-sensitive-breast-cancer-who-remain-premenopausal-or-regain-menstruation-after-chemotherapy-astrra-study-protocol-for-a-randomized-controlled-trial-and-progress
#16
Hyun-Ah Kim, Sei Hyun Ahn, Seok Jin Nam, Seho Park, Jungsil Ro, Seock-Ah Im, Yong Sik Jung, Jung Han Yoon, Min Hee Hur, Yoon Ji Choi, Soo-Jung Lee, Joon Jeong, Se-Heon Cho, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Byung-In Moon, Tae Hyun Kim, Chanheun Park, Sei Joong Kim, Sung Hoo Jung, Heungkyu Park, Geum Hee Gwak, Sun Hee Kang, Jong Gin Kim, Jeryong Kim, Su Yun Choi, Cheol-Wan Lim, Doyil Kim, Youngbum Yoo, Young-Jin Song, Yoon-Jung Kang, Sang Seol Jung, Hyuk Jai Shin, Kwan Ju Lee, Se-Hwan Han, Eun Sook Lee, Wonshik Han, Hee-Jung Kim, Woo Chul Noh
BACKGROUND: Ovarian function suppression (OFS) has been shown to be effective as adjuvant endocrine therapy in premenopausal women with hormone receptor-positive breast cancer. However, it is currently unclear if addition of OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy results in a survival benefit. In 2008, the Korean Breast Cancer Society Study Group initiated the ASTRRA randomized phase III trial to evaluate the efficacy of OFS in addition to standard tamoxifen treatment in hormone receptor-positive breast cancer patients who remain or regain premenopausal status after chemotherapy...
May 19, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27160475/salvage-radiotherapy-with-or-without-short-term-hormone-therapy-for-rising-prostate-specific-antigen-concentration-after-radical-prostatectomy-getug-afu-16-a-randomised-multicentre-open-label-phase-3-trial
#17
Christian Carrie, Ali Hasbini, Guy de Laroche, Pierre Richaud, Stéphane Guerif, Igor Latorzeff, Stéphane Supiot, Mathieu Bosset, Jean-Léon Lagrange, Véronique Beckendorf, François Lesaunier, Bernard Dubray, Jean-Philippe Wagner, Tan Dat N'Guyen, Jean-Philippe Suchaud, Gilles Créhange, Nicolas Barbier, Muriel Habibian, Céline Ferlay, Philippe Fourneret, Alain Ruffion, Sophie Dussart
BACKGROUND: How best to treat rising prostate-specific antigen (PSA) concentration after radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need for more aggressive treatment such as long-term androgen suppression, but fewer than half of patients benefit from it. We aimed to establish the effect of adding short-term androgen suppression at the time of salvage radiotherapy on biochemical outcome and overall survival in men with rising PSA following radical prostatectomy...
June 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27125966/epirubicin-dose-and-sequential-hormonal-therapy-mature-results-of-the-hmfec-randomised-phase-iii-trial-in-premenopausal-patients-with-node-positive-early-breast-cancer
#18
R C Coombes, L S Kilburn, N Tubiana-Mathieu, T Olmos, A Van Bochove, F R Perez-Lopez, C Palmieri, J Stebbing, J M Bliss
BACKGROUND: The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node positive breast cancer and to the benefits of tailored endocrine therapy in such patients. PATIENTS AND METHODS: HMFEC was a multi-centre, phase III, open label, randomised controlled trial with a 2 × 2 factorial design. Eligible patients were premenopausal with node positive early breast cancer; significant cardiac disease or uncontrolled hypertension was exclusion criterion...
June 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27112139/hormonal-therapy-might-be-a-better-choice-as-maintenance-treatment-than-capecitabine-after-response-to-first-line-capecitabine-based-combination-chemotherapy-for-patients-with-hormone-receptor-positive-and-her2-negative-metastatic-breast-cancer
#19
Xue-Lian Chen, Feng Du, Ruo-Xi Hong, Jia-Yu Wang, Yang Luo, Qing Li, Ying Fan, Bing-He Xu
BACKGROUND: Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. However, no clinical trials have directly compared the efficacy of MCT and HT after response to first-line capecitabine-based combination chemotherapy (FCCT) in patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer...
2016: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/27073671/hydronephrosis-associated-with-ureteral-metastasis-of-prostate-cancer-a-rare-case-report
#20
Dong Zhang, Hongliang Li, Weimin Gan
Prostate cancer is one of the most common male malignancies, although it rarely metastasizes to the ureter. The present case study reported a 63-year-old man who presented with asymptomatic right hydronephrosis, detected by ultrasound. Computed tomography urography demonstrated right hydronephrosis, secondary to thickening of the distal ureter. The patient's serum concentration of prostate specific antigen was 111.400 ng/ml, and a prostate needle biopsy revealed prostate adenocarcinoma, with a Gleason score of 4+5=9...
April 2016: Molecular and Clinical Oncology
keyword
keyword
36607
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"